IRADIMED CORP
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 18, 2026 | During market hours | $20.50M | $0.41 | $0.46 |
| Q1 FY2026 Ended Mar 31, 2026 | May 1, 2026 | Before market open | $22.00M | $0.45 | $0.49 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 10, 2026 | Before market open | $22.70M | $0.50 | $0.54 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $21.20M | $0.43 | $0.47 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 1, 2025 | Before market open | $20.40M | $0.45 | $0.49 |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | $19.50M | $0.37 | $0.42 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | $19.40M | $0.40 | $0.44 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $18.30M | $0.40 | $0.43 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 18, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| non-GAAP diluted earnings per sharenon-GAAP | third quarter of 2026 | $0.54 to $0.59 | New |
| non-GAAP diluted earnings per sharenon-GAAP | full year 2026 | $2.09 to $2.24 | Raised |
| GAAP diluted earnings per shareGAAP | third quarter of 2026 | $0.49 to $0.54 | New |
| GAAP diluted earnings per shareGAAP | full year 2026 | $1.90 to $2.05 | Maintained |
| revenue | full year 2026 | $91.00M to $96.00M | Maintained |
| revenue | third quarter of 2026 | $23.00M to $24.50M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Iradimed filed with the SEC
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K/A
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
I R ADIMED Announces Special Cash Dividend of $0.50 Per Share
Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION ANNOUNCES BOARD TRANSITION: ANTHONY VUOTO RETIRES, JOE KIANI APPOINTED AS NEW DIRECTOR
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
QUARTERLY AND SPECIAL DIVIDEND PRESS RELEASE
Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes
Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
CORPORATION Announces Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Preliminary Financial Results for
Results of operations · EX-99.1 to Form 8-K
CORPORATION Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED CORPORATION Withdraws 510(k) with Plans to
Results of operations · Other events · EX-99.1 to Form 8-K
IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
CORPORATION Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
IRADIMED Announces Special $1.00 Per Share Cash Dividend
Other events · EX-99.1 to Form 8-K
CORPORATION Announces Fourth Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
CORPORATION Announces Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K